Immunotherapy for young people with a specific brain tumor
Treatments studied
Part of Cancer clinical trials.
This trial is testing a new immunotherapy (nivolumab) for children, teens, and young adults with a specific type of aggressive brain tumor (glioblastoma that has a DNA repair problem). It aims to see if giving this treatment early, right after surgery, can help the immune system fight the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 and 25 years old.
- You have a glioblastoma that shows a specific genetic change called 'replication-repair deficiency' (RRD).
- Your tumor was removed completely or almost completely by surgery.
- You have not received any other treatment for this tumor, like chemotherapy or radiation.
- You have not used steroids (like prednisone) for your brain tumor in the last 7 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (relatlimab and nivolumab) for newly diagnosed high-grade gliomas and brainstem tumors that have specific genetic mutations. The goal is to see if this treatment approach can help your immune system fight the cancer.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
This trial tests whether two immunotherapy drugs, nivolumab and relatlimab, can help treat glioblastoma (GBM), a type of brain tumor. It is for people newly diagnosed or who haven't had radiation or chemotherapy yet and are scheduled for surgery.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This trial studies how brain tumors (like high-risk gliomas, medulloblastoma, and ependymoma) respond to treatment and why they sometimes become resistant. It is for young people aged 15 to 39 and aims to use tumor tissue samples to understand the tumor better and guide future therapies.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.